Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aeterna, EMD Serono finalize promotional services agreement for Saizen in US
Saizen is a recombinant human Growth Hormone (r-hGH) registered in the US to treat growth hormone deficiency (GHD) in children and adults. As part of the deal, Aeterna
Saizen is a recombinant human Growth Hormone (r-hGH) registered in the US to treat growth hormone deficiency (GHD) in children and adults. As part of the deal, Aeterna
Under the deal, a Phase I/II trial will be conducted to evaluate the combination of Plexxikon’s investigational CSF-1R inhibitor, PLX3397, and Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), which provides
The start of field-based commercialization efforts for Xalkori is part of the company’s aim to bring treatment options for challenging cancers to patients. In the US, Xalkori is
EpiTherapeutics has developed a library of first-in-class, selective small molecule inhibitors of epigenetic regulation of gene transcription, in particular histone demethylases. Gilead Research and Development executive vice-president and
Venetoclax is an inhibitor of the B-cell lymphoma-2 (BCL-2) protein, which AbbVie is currently developing in partnership with Genentech and Roche. It is designed to selectively inhibit the
Located in Kendall Square, the new Lilly Cambridge Innovation Center will allow leading life science experts and organizations to explore how emerging technologies and connectivity can advance drug
The program includes two replicate studies evaluating 48 week viral suppression with a two drug regimen combining dolutegravir and rilpivirine in HIV patients who have already achieved viral
The transaction, which has been unanimously approved by Boards of Directors from both companies, will strengthen Alexion’s business in developing and commercializing transformative therapies for patients with devastating
According to the company, the decision taken to retain existing holding in ViiV Healthcare reflects on its updated strong positive outlook. ViiV Healthcare, is a joint venture with
PKAN is believed to affect about one to three persons per million worldwide and there are currently no approved treatment available. The company has started the screening of